• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Neuroendocrine tumors respond to somatostatin-guided radiotherapy

Article

CONTEXT: Indium-labeled somatostatin formed the first wave of cell-surface receptor scintigraphy in the mid-1990s. While its value was limited to diagnosing and staging neuroendocrine tumors (NET), the molecularly based agent has proved superior to CT and MR in these roles. Dr. Eric P. Krenning of Erasmus University Medical Center in the Netherlands has expanded its role by labeling somatostatin with therapeutic radionuclides, producing a peptide-receptor therapy.

RESULTS: More than 400 patients with NET-expressing somatostatin receptors have undergone radiotherapy at the Erasmus hospital since 1992. The standard protocol employs a somatostatin targeting agent and either lutetium-177 or yttrium-90 beta-particle emitters for therapy. The approach has proved increasingly effective at shrinking tumors, especially with the third-generation analog lutetium-177 DOTA-Tyr3 octreotide, according to Krenning.

Treatments involving three or four sessions over eight to nine weeks have cut the volume of tumors in more than half for 20% to 30% of patients. On average, the effect of the second-generation analog lasts for at least 36 months, helping to reduce fatigue, insomnia, and pain. More than half of the patients treated with the second-generation analog have survived at least five years.

IMPLICATIONS: Although molecular imaging is billed as the next big thing in radiology, it has had a decade-long influence on the diagnosis, staging, and treatment of neuroendocrine tumors. Data suggest that patients receiving somatostatin receptor-guided therapy have fewer symptoms and longer survival than patients treated with chemotherapy. Krenning reported his results at the Society for Molecular Imaging meeting in September.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.